Gazyva

Active Ingredient(s): Obinutuzumab
FDA Approved: * November 1, 2013
Pharm Company: * GENENTECH
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Gazyva Overview

Obinutuzumab (called afutuzumab until 2009)[1] is a humanized anti-CD20 monoclonal antibody, originated by GlycArt Biotechnology AG and developed by Roche as a cancer treatment. It can be used as a first-line treatment for chronic lymphocytic leukemia in combination with chemotherapy or with venetoclax, as a first-line treatment for follicular lymphoma in combination with chemotherapy, and as treatment for relapsed or refractory follicular lymphoma in combination with bendamus...

Read more Gazyva Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Obinutuzumab

Recent Gazyva Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Obinutuzumab
  • Injection: 1000mg/40ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Gazyva: (1 result)

Sorted by National Drug Code
  • 50242-070 Gazyva 1000 mg/40ml Intravenous Injection, Solution, Concentrate by Genentech, Inc.

Other drugs which contain Obinutuzumab or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 September 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA